BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14975509)

  • 21. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The roles of human viruses in the pathogenesis of lymphoma.
    Lyons SF; Liebowitz DN
    Semin Oncol; 1998 Aug; 25(4):461-75. PubMed ID: 9728596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV transformation overrides gene expression patterns of B cell differentiation stages.
    Siemer D; Kurth J; Lang S; Lehnerdt G; Stanelle J; Küppers R
    Mol Immunol; 2008 Jun; 45(11):3133-41. PubMed ID: 18430472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
    Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
    J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus-associated lymphoproliferative disorders.
    Ambinder RF
    Rev Clin Exp Hematol; 2003 Dec; 7(4):362-74. PubMed ID: 15129648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
    Rohr JC; Wagner HJ; Lauten M; Wacker HH; Jüttner E; Hanke C; Pohl M; Niemeyer CM
    Pediatr Transplant; 2008 Jun; 12(4):426-31. PubMed ID: 18466428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-MYC impairs immunogenicity of human B cells.
    Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
    Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
    Allday MJ
    Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus-associated lymphomas.
    Gandhi MK
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):77-89. PubMed ID: 16441211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
    Niller HH; Wolf H; Minarovits J
    Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of EBERs in oncogenesis.
    Takada K; Nanbo A
    Semin Cancer Biol; 2001 Dec; 11(6):461-7. PubMed ID: 11669608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV-associated lymphoproliferative disorders: classification and treatment.
    Carbone A; Gloghini A; Dotti G
    Oncologist; 2008 May; 13(5):577-85. PubMed ID: 18515742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
    Beck Z; Illés A; Keresztes K; Bessenyei B; Szöllosi Z; Kis A; Oláh E
    Orv Hetil; 2006 Aug; 147(33):1539-44. PubMed ID: 17037676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection with Epstein-Barr virus and cancer: an epidemiological review.
    Serraino D; Piselli P; Angeletti Cl; Scuderi M; Ippolito G; Capobianchi MR
    J Biol Regul Homeost Agents; 2005; 19(1-2):63-70. PubMed ID: 16178276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lymphoma genesis in the context of HIV infection].
    Besson C; Raphaël M
    Ann Med Interne (Paris); 2003 Dec; 154(8):523-8. PubMed ID: 15037828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of Epstein Barr virus latent membrane protein-1 30 bp deletion in a series of pediatric malignancies in Argentina.
    Chabay P; De Matteo E; Merediz A; Preciado MV
    Arch Virol; 2004 Aug; 149(8):1515-26. PubMed ID: 15290377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EBV the prototypical human tumor virus--just how bad is it?
    Thorley-Lawson DA
    J Allergy Clin Immunol; 2005 Aug; 116(2):251-61; quiz 262. PubMed ID: 16083776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telomere size and telomerase activity in Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cell lines.
    Mochida A; Gotoh E; Senpuku H; Harada S; Kitamura R; Takahashi T; Yanagi K
    Arch Virol; 2005 Oct; 150(10):2139-50. PubMed ID: 15986178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.
    Teitell MA; Lones MA; Perkins SL; Sanger WG; Cairo MS; Said JW
    Am J Clin Pathol; 2005 Oct; 124(4):569-75. PubMed ID: 16146820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.